Standout Papers

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis 2017 2026 2020 2023 555
  1. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis (2017)
    Michael E. Wechsler, Praveen Akuthota et al. New England Journal of Medicine

Immediate Impact

53 standout
Sub-graph 1 of 23

Citing Papers

Inflammatory response of nanoparticles: Mechanisms, consequences, and strategies for mitigation
2024 Standout
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
2024 Standout
3 intermediate papers

Works of Jonathan Steinfeld being referenced

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
2020
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
2017 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Jonathan Steinfeld 706 381 755 516 34 1.2k
Claudia Sengler 290 114 221 326 43 1.2k
H. Jeffrey Wilkins 427 550 383 589 21 1.3k
Caroline J. Poulton 301 89 866 183 39 1.4k
J.-F. Cordier 202 211 949 485 47 1.3k
Karina Raimundo 324 32 687 394 56 1.1k
Carol A. McAlear 564 94 879 188 43 1.1k
Minako Tomiita 220 253 118 200 53 1.1k
Philippe Delaval 501 102 770 308 18 915
Ruchika Goel 325 102 607 85 61 1.0k
Tuyet‐Hang Pham 148 221 296 418 19 1.1k

All Works

Loading papers...

Rankless by CCL
2026